- Inhibrx Inc INBX has initiated a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma, a type of bone cancer that develops in cartilage cells.
- The primary objective is to evaluate the anticancer efficacy of INBRX-109, as measured by progression-free survival.
- Patients with disease progression on placebo will be able to crossover to INBRX-109. An interim analysis will occur after 50% of the planned PFS events are observed.
- Additionally, Inhibrx's loan agreement with Oxford Finance was amended, and it received $40M in additional principal on June 18.
- Inhibrx also provided updated results from an ongoing Phase 1 trial of INBRX-109 in chondrosarcoma.
- Additional data will be presented at the Annual Connective Tissue Oncology Society Conference in November.
- Disease control was observed in 14 of 16 patients (87.5%).
- Two patients achieved partial responses, and 12/16 patients had stable disease.
- Based on preliminary results of the ongoing Phase 1 study, the median progression-free survival is 7.6 months, and the median overall survival has not been reached.
- Three patients have exceeded 52 weeks on treatment with INBRX-109, with 62 weeks being the most prolonged duration of stable disease observed to date, with the patient still on study.
- The safety and tolerability profile was favorable, with only 1/16 patients experiencing a transient low grade and a fully reversible sign of hepatotoxicity.
- The trial is ongoing, with an additional 12 slots added for patients with IDH1 or IDH2 mutations.
- Price Action: INBX shares closed at $26.33 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
